生血宁片联合罗沙司他胶囊对维持性血液透析相关贫血的应用价值
The Application Value of Shengxuening Tablets Combined with Roxadustat Capsules in Maintenance Hemodialysis Related Anemia
姚丽君 1聂子牧1
作者信息
摘要
目的 观察生血宁片联合罗沙司他胶囊对维持性血液透析相关贫血(MHDA)的应用价值.方法 本研究为前瞻性研究,研究对象为许昌市立医院2022年10月至2023年10月期间收治的112例慢性肾衰竭(CRF)患者,应用计算机生成随机序列并进行分配隐藏后,将其分别列为常规组(56例)和联合组(56例),两组均实施维持行血液透析(MHD)治疗,常规组MHD治疗期间予以服用罗沙司他胶囊配合治疗,联合组在常规组的治疗基础上,联合应用生血宁片配合治疗,治疗结束后随访一年.比较两组铁代谢指标,炎症指标,血液指标及预后情况.结果 在不同治疗方案下,联合组的血清铁(SI)、血清铁蛋白(SF)、总铁结合力(TIBC)、血清转铁蛋白饱和度(TSAT)均高于常规组,差异有统计学意义(P＜0.05).联合组的C-反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、降钙素原(PCT)均低于常规组,差异有统计学意义(P＜0.05).联合组的血红蛋白(Hb)、红细胞计数(RBC)、红细胞比容(HCT)、平均红细胞体积(MCV)均高于常规组,差异有统计学意义(P＜0.05).截至随访结束时,联合组不良预后的发生率3.57％低于常规组19.64％,差异有统计学意义(P＜0.05).结论 生血宁片联合罗沙司他胶囊能改善MHDA患者的铁代谢情况并改善机体微炎症状态,对促进患者血液指标恢复并降低不良预后发生风险均有积极意义.
Abstract
Objective Observation of the application value of shengxuening tablets combined with roxadustat capsules in maintenance hemodialysis related anemia(MHDA).Methods This study was a prospective study,with 112 patients with chronic kidney failure(CRF)admitted to Xuchang Municipal Hospital from October 2022 to October 2023.After generating a computer-generated random sequence and assigning it to a hidden group,they were divided into a conventional group(56 cases)and a combination group(56 cases).Both groups received maintain hemodialysis(MHD)treatment,during the MHD treatment,the conventional group received roxadustat capsules,while the combination group received shengxuening tablets on the basis of the conventional group.After treatment,they were followed up for one year.Compare the iron metabolism indicators,inflammation indicators,blood indicators,and prognosis of the two groups.Results Under different treatment plans,the serum iron(SI),serum ferritin(SF),total iron binding capacity(TIBC),and serum transferrin saturation(TSAT)in the combination group were higher than those in the conventional group,and the differences were statistically significant(P＜0.05).The levels of C-reactive protein(CRP),interleukin-6(IL-6),interleukin-8(IL-8),and procalcitonin(PCT)in the combination group were lower than those in the conventional group,and the differences were statistically significant(P＜0.05).The hemoglobin(Hb),red blood cell count(RBC),hematocrit(HCT),and mean corpuscular volume(MCV)of the combination group were higher than those of the conventional group,and the differences were statistically significant(P＜0.05).As of the end of follow-up,the incidence of poor prognosis in the combination group was 3.57％lower than that in the conventional group's 19.64％,and the difference was statistically significant(P＜0.05).Conclusion The combination of shengxuening tablets and roxadustat capsules can improve the iron metabolism of MHDA patients and alleviate the body's micro inflammatory state,which has a positive effect on promoting the recovery of blood indicators and reducing the risk of adverse prognosis.
关键词
维持性血液透析相关贫血/生血宁片/罗沙司他胶囊/铁代谢/微炎症状态Key words
Maintenance hemodialysis related anemia/Shengxuening tablets/Roxadustat capsules/Iron metabolism/Micro inflammatory state引用本文复制引用
出版年
2025
NETL
NSTL
万方数据